All In Biotech

Drug Trial Radar · NCT07142837

Study of ZG005 in Combination With Gecacitinib and Chemotherapy for Participants With Advanced Solid Tumors

A Study to Evaluate the Efficacy and Safety of ZG005 in Combination With Gecacitinib and Chemotherapy for Participants With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Aug 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 153 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

153

Planned (sponsor's estimate)

Start

Sep 2025

Primary completion

Oct 2027

Study completion Dec 2027

Sponsor

Sponsor type
Industry
First posted
Aug 27, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open-label phase I/II study for participants with advanced solid tumors who have failed prior immune checkpoint inhibitor therapies.

Conditions

  • Advanced Solid Tumor

Interventions

  • ZG005Drug

    ZG005 20mg/kg; once every 3 weeks;IV infusion

  • GecacitinibDrug

    Gecacitinib for dose escalations are set as 100mg Bid po. Gecacitinib for dose expansion will commence after the Recommended Phase 2 Dose (RP2D) is determined during the dose-escalation stage.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Limiting Toxicity (DLT)Time frame: During the first 28 days
  2. Objective Response Rate (ORR)Time frame: Up to 2 years
  3. Adverse events (AEs)Time frame: Up to 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chinese PLA General Hosptial

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.